Tatva Chintan Pharma Chem Limited has informed the Exchange regarding 'Communication to Shareholders - Dividend for FY 2024-25 - Intimation on Tax Deduction at source (TDS) / withholding tax on Dividend'.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem has sent shareholders a detailed note on how tax will be deducted at source (TDS) on the FY2024-25 dividend of Rs. 1.00 (10%) per share (face value Rs. 10), recommended by the Board on 2 May 2025 and pending approval at the 29th AGM. TDS will be 10% for resident shareholders with valid PAN, 20% if PAN is missing/invalid or not linked with Aadhaar, and NIL for resident individuals whose total dividend from the company does not exceed Rs. 10,000 in the financial year. Non-resident shareholders will face 20% TDS (plus surcharge and cess) unless they provide Tax Residency Certificate, Form 10F, and other documents to claim DTAA treaty benefits. Shareholders must submit relevant forms (15G, 15H, declarations) to the company's RTA MUFG Intime India by 11 September 2025, after which no changes to TDS will be entertained.
This is a routine procedural communication and not a new dividend announcement. Shareholders should ensure PAN is linked with Aadhaar and submit the right forms before 11 September 2025 to avoid excess TDS deduction; otherwise they will need to claim refunds via their income tax return.